Adreic Therapeutics

Adreic Therapeutics is a clinical-stage biotechnology company specializing in the development of targeted alpha therapies (TAT) for the treatment of rare and aggressive cancers. The company's platform utilizes the alpha-emitting isotope Lead-212, which is conjugated to highly specific targeting moieties to deliver lethal radiation directly to tumor cells. Its lead program, ADR-001, is a Lead-212 labeled monoclonal antibody targeting GD2 ganglioside for the treatment of pediatric neuroblastoma. Additionally, Adreic is developing ADR-002, a small molecule radiopharmaceutical targeting PSMA for prostate cancer, alongside other programs for solid tumors. By leveraging proprietary targeting technologies and advanced radiochemistry, the company aims to provide more effective and less toxic treatment options for patients with advanced malignancies.